Haemonetics Corporation prepares to unveil Q3 2026 financial results

Haemonetics Corporation (NYSE: HAE) announced that its third‑quarter fiscal 2026 results, covering the period ending December 27 2025, will be released on its Investor Relations website at www.haemonetics.com . The company will host a conference call and webcast at 8:00 a.m. ET on February 5 2026 to discuss the outcomes and address questions from investors and analysts.

Context

  • Sector & industry: Haemonetics operates within the Health Care sector, specifically in Health Care Equipment & Supplies, designing and manufacturing automated blood‑processing systems for surgical blood salvage, blood component collections, and plasma collections.
  • Financial backdrop: As of February 3, 2026, the stock closed at $65.95, with a 52‑week high of $87.32 (December 9, 2025) and a 52‑week low of $47.32 (September 25, 2025). The market cap stands at approximately $3.04 billion, and the price‑earnings ratio is 18.93.
  • Strategic outlook: Analysts have maintained an “Outperform” rating for the company. Barrington Research set a price objective of $93.00, indicating a potential upside of 43.8% from the current trading level. Other analysts have varied in their recommendations, with some downgrading from “Buy” to “Hold.”

Upcoming Q3 release

The scheduled webcast will provide an opportunity for Haemonetics’ management to elaborate on operational metrics, product pipeline developments, and market dynamics that influence the company’s performance. Investors and analysts will be able to:

  • Review the detailed earnings presentation, which will include revenue figures, earnings per share, and guidance for the remainder of the fiscal year.
  • Examine the impact of global demand for blood‑processing equipment and any regulatory changes affecting the healthcare equipment market.
  • Discuss the company’s strategy for maintaining competitiveness amid evolving technology and healthcare reimbursement landscapes.

Market reaction and analyst sentiment

While the company’s stock has demonstrated volatility—trading between $47.32 and $87.32 in the past year—analysts remain cautiously optimistic. Barrington Research’s reaffirmation of the “Outperform” rating, coupled with a robust price target, suggests confidence in Haemonetics’ growth prospects. However, other firms, such as Needham & Company LLC, have downgraded the stock from a “Buy” to a “Hold,” reflecting a spectrum of market expectations.

Conclusion

Haemonetics Corporation’s forthcoming third‑quarter earnings presentation is a key event for stakeholders seeking insight into the company’s financial health and strategic direction. By providing transparent results and engaging directly with investors, Haemonetics aims to reinforce its position in the competitive healthcare equipment sector and to clarify the trajectory of its earnings growth.